Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.

J Eur Acad Dermatol VenereolMay 26, 2026 (epub)
Clinical ResearchDermatology

Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas et al.

✦ AI-curated · Sources linked

In 30 seconds

This large-scale meta-analysis evaluated the infection risk associated with JAK-STAT inhibitors in over 29,000 patients with immune-mediated inflammatory diseases. The study found that these inhibitors significantly increased the risk of influenza (RR = 2.12), bronchitis (RR = 2.03), and herpes zoster (RR = 1.67) compared to placebo, particularly in patients with atopic dermatitis.

Key findings

  • JAK-STAT inhibitors increased the risk of influenza (RR = 2.12, 95% CI 1.03-4.36) compared to placebo.
  • The risk of bronchitis was elevated (RR = 2.03, 95% CI 1.43-2.88) in patients using JAK-STAT inhibitors.
  • Herpes zoster risk was also higher (RR = 1.67, 95% CI 1.29-2.15) with JAK-STAT inhibitors.
  • Topical JAK-STAT inhibitors showed a safety profile comparable to vehicle controls.

Why it matters

Understanding the infection risks associated with JAK-STAT inhibitors is crucial for clinicians managing patients with immune-mediated inflammatory diseases. Awareness of these risks can guide vaccination and preventive strategies, particularly for vulnerable populations.

What to keep in mind

The included studies involved highly selected populations with few comorbidities and short follow-up.

Source

PubMed · PMID 42187316

Published in J Eur Acad Dermatol Venereol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.